As for SCCA-IgM isoforms and liver cancer, our findings clearly document a graduate decrease of serpinB4-IgM/serpinB3-IgM ratio when comparing patients with different extent of liver disease, despite not reaching statistically significant differences due to the limited number of the patients included in the study. This evidence concerns the gene SERPINB4 and liver cancer.